"Nitroimidazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
IMIDAZOLES having a nitro moiety.
Descriptor ID |
D009593
|
MeSH Number(s) |
D02.640.672 D03.383.129.308.658
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nitroimidazoles".
Below are MeSH descriptors whose meaning is more specific than "Nitroimidazoles".
This graph shows the total number of publications written about "Nitroimidazoles" by people in this website by year, and whether "Nitroimidazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 |
2000 | 1 | 1 | 2 |
2009 | 0 | 1 | 1 |
2014 | 0 | 2 | 2 |
2015 | 1 | 1 | 2 |
2016 | 2 | 1 | 3 |
2017 | 1 | 2 | 3 |
2018 | 3 | 1 | 4 |
2019 | 1 | 4 | 5 |
2020 | 1 | 1 | 2 |
2021 | 2 | 0 | 2 |
2022 | 0 | 1 | 1 |
2023 | 6 | 0 | 6 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nitroimidazoles" by people in Profiles.
-
Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response. Clin Microbiol Infect. 2024 Sep; 30(9):1207-1208.
-
Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe. Clin Microbiol Infect. 2024 Sep; 30(9):1197.e1-1197.e4.
-
The impact of vaccine-linked chemotherapy on liver health in a mouse model of chronic Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2023 Nov; 17(11):e0011519.
-
[Treatment of MDR, pre-XDR, XDR and rifampicin resistant tuberculosis or in case of intolerance to at least rifampicin in Austria, Germany and Switzerland - Amendment dated 19.09.2023 to the Sk2-Guideline: Tuberculosis in adulthood of the German Central Committee against Tuberculosis (DZK) on behalf of the German Respiratory Society (DGP)]. Pneumologie. 2024 Jan; 78(1):35-46.
-
Localized cardiac small molecule trajectories and persistent chemical sequelae in experimental Chagas disease. Nat Commun. 2023 10 25; 14(1):6769.
-
Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant Clostridioides difficile. Nat Commun. 2023 07 12; 14(1):4130.
-
Frequency Variation and Dose Modification of Benznidazole Administration for the Treatment of Trypanosoma cruzi Infection in Mice, Dogs, and Nonhuman Primates. Antimicrob Agents Chemother. 2023 05 17; 67(5):e0013223.
-
Pretomanid-resistant tuberculosis. J Infect. 2023 05; 86(5):520-524.
-
Vaccine-linked chemotherapy with a low dose of benznidazole plus a bivalent recombinant protein vaccine prevents the development of cardiac fibrosis caused by Trypanosoma cruzi in chronically-infected BALB/c mice. PLoS Negl Trop Dis. 2022 09; 16(9):e0010258.
-
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. Clin Cancer Res. 2021 06 01; 27(11):3050-3060.